Nonetheless,given the central role played by HIF-1 and HIF-2 in the survival andgrowth of the majority of solid tumors and the direct correlationbetween HIF-α levels and patient mortality in many cancers,51,52 a therapeutic agent that directly inhibits both HIF-1 and HIF2 isexpected to be of significant benefit to cancer patients. The gene discussed is HIF1A; the disease is cancer.